MC
LGND icon

Maplelane Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Maplelane Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-432,810
Closed -$26.9M – 150
2020
Q4 		$26.9M Buy
432,810
+192,360
+80% +$11M 0.34% 79
2020
Q3 		$14.3M Buy
240,450
+48,090
+25% +$3.28M 0.26% 80
2020
Q2 		$13.4M Sell
192,360
-176,330
-48% -$11.2M 0.25% 76
2020
Q1 		$16.7M Buy
368,690
+104,195
+39% +$5.91M 0.77% 40
2019
Q4 		$17.2M Sell
264,495
-200,375
-43% -$13.4M 0.47% 56
2019
Q3 		$28.9M Buy
+464,870
New +$29.2M 0.65% 45
2019
Q1 		– Sell
-561,050
Closed -$47.5M – 132
2018
Q4 		$47.5M Buy
+561,050
New +$59.8M 1.38% 23

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Maplelane Capital's LGND Position: Q1 2019 in Review

Maplelane Capital sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 2 shares.

Maplelane Capital first reported a position in LGND in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Maplelane Capital reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Maplelane Capital sold 2 Ligand Pharmaceuticals shares in Q1 2019.
  • Maplelane Capital first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Maplelane Capital's Ligand Pharmaceuticals position peaked at $0 in Q4 2018.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Maplelane Capital's 13F filing for Q1 2019, filed 15 May 2019.